Skip to Main Content

Paper Details

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
Oncotarget
35
2016
Author NameAffiliation
Michael PeytonHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center
John D MinnaHamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center
John D MinnaSimmons Cancer Center, University of Texas Southwestern Medical Center
John D MinnaUniversity of Texas Southwestern Medical Center
John D MinnaUniversity of Texas Southwestern Medical Center
  • 1 - 5

Datasets

Release 1.2